亚宝药业集团股份有限公司关于控股股东进行股票质押式回购交易的公告

Core Viewpoint - The announcement details the stock pledge and repurchase activities of Yabao Pharmaceutical Group Co., Ltd, highlighting the significant shareholding and the ongoing share repurchase program [2][5]. Group 1: Stock Pledge Information - As of the announcement date, the controlling shareholder, Shanxi Yabao Investment Group Co., Ltd, holds 94,300,000 shares, accounting for 13.47% of the total share capital [2]. - A total of 26,850,000 shares have been pledged, representing 28.47% of the shares held by the controlling shareholder and 3.84% of the company's total share capital [2]. - The pledged shares are not used as collateral for major asset restructuring or other guarantees [2]. Group 2: Share Repurchase Program - The company approved a share repurchase plan on May 16, 2025, with a total fund amount between RMB 50 million and RMB 100 million, and a maximum repurchase price of RMB 6.95 per share [7]. - As of October 31, 2025, the company has repurchased 8,000,000 shares, which is 1.14% of the total share capital, with a total expenditure of RMB 52,151,912.00 [8]. - The highest and lowest transaction prices during the repurchase were RMB 6.65 and RMB 6.30 per share, respectively [8].